It's the first prescription hair regrowth gummy to hit the market, and it offers women a more convenient way to stay ...

Dilley doesn’t recommend using apple cider vinegar capsules or gummies, which aren’t regulated by the FDA. These supplements ...

The Apple Cider Gummies That Make Vitamins Easier To Take. More for You. Bill Clinton on opposing President Trump's agenda: "We cannot throw the legacy of this country away" ...

Moderna said the FDA approved its new COVID-19 vaccine "for use in all adults 65 and older, as well as individuals aged 12-64 years with at least one or more underlying risk factor." ...

AI-driven Clairity Breast platform, now FDA-approved, predicts five-year breast cancer risk from mammograms, enhancing early detection and prevention.

The FDA approved Moderna’s lower-dose COVID-19 vaccine, but only for individuals aged 65 years or older and people aged 12 to 64 years at high risk for severe disease, aligning with the agency ...

For people diagnosed with macular telangiectasia type 2 (MacTel)—a rare and slowly progressing retinal disease—there have been no FDA-approved (or other) treatments to slow or stop vision loss.

The US FDA has approved Moderna's new COVID-19 vaccine, mNEXSPIKE, amidst emerging coronavirus variants. It is approved for adults 65 and older, and individuals aged 12-64 with underlying risk ...

Moderna has announced the FDA approval of a new, lower-dose messenger RNA (mRNA) vaccine against COVID-19, called mNEXSPIKE (mRNA-1283) (1).The product joins Moderna’s original COVID vaccine, Spikevax ...

The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement for the company's existing shot, but a second option.

The FDA approved mRNA-1283, marketed under the name mNEXSPIKE, for all adults 65 and older and 12- to 64-year-olds with at least one condition that puts them at risk for severe outcomes of COVID-19.

Novartis has a third FDA-approved indication for its oral therapy for complement-mediated diseases – Fabhalta – after getting a green light in ultra-rare kidney disease C3 glomerulopathy (C3G).